Skip to Main Content

Paper Details

Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment.
Cancer Res Commun
0
2023
ASCT, Hematological Diseases, MRD, Multiple Myeloma, Patients, Stem Cell, cytogenetic abnormalities, multiple myeloma, myeloma, patients, stem cell, tumor
Author NameAffiliation
Kenneth C AndersonLeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School
Kenneth C AndersonLeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School
  • 1 - 2

Datasets

Release 1.2